Integra Lifesciences Holdings Corp (NASDAQ:IART) – Stock analysts at Piper Jaffray Companies dropped their FY2018 earnings estimates for shares of Integra Lifesciences in a research note issued on Wednesday, October 31st. Piper Jaffray Companies analyst M. O’brien now anticipates that the life sciences company will earn $2.39 per share for the year, down from their prior forecast of $2.40. Piper Jaffray Companies also issued estimates for Integra Lifesciences’ Q4 2019 earnings at $0.70 EPS, FY2019 earnings at $2.61 EPS and FY2020 earnings at $2.94 EPS.
Several other analysts have also recently weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $69.00 price objective on shares of Integra Lifesciences in a research report on Wednesday, September 12th. Zacks Investment Research cut Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 25th. BidaskClub raised Integra Lifesciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Bank of America cut Integra Lifesciences from a “neutral” rating to an “underperform” rating in a research report on Tuesday, August 7th. They noted that the move was a valuation call. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Integra Lifesciences in a research report on Friday, August 17th. One analyst has rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $61.83.
Integra Lifesciences (NASDAQ:IART) last posted its earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.59. The company had revenue of $365.85 million for the quarter, compared to analysts’ expectations of $367.89 million. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. Integra Lifesciences’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the firm earned $0.45 earnings per share.
Several hedge funds have recently added to or reduced their stakes in IART. FMR LLC lifted its holdings in shares of Integra Lifesciences by 11.8% during the second quarter. FMR LLC now owns 11,078,120 shares of the life sciences company’s stock valued at $713,542,000 after purchasing an additional 1,166,483 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Integra Lifesciences during the second quarter valued at approximately $46,263,000. Janus Henderson Group PLC lifted its holdings in shares of Integra Lifesciences by 22.8% during the second quarter. Janus Henderson Group PLC now owns 1,966,341 shares of the life sciences company’s stock valued at $126,652,000 after purchasing an additional 365,254 shares during the last quarter. First Trust Advisors LP raised its holdings in Integra Lifesciences by 472.3% in the 3rd quarter. First Trust Advisors LP now owns 389,720 shares of the life sciences company’s stock worth $25,671,000 after acquiring an additional 321,619 shares during the last quarter. Finally, Castleark Management LLC purchased a new position in Integra Lifesciences in the 2nd quarter worth approximately $18,130,000. Hedge funds and other institutional investors own 84.33% of the company’s stock.
In other news, VP Glenn Coleman sold 8,916 shares of Integra Lifesciences stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $63.00, for a total transaction of $561,708.00. Following the completion of the transaction, the vice president now directly owns 16,795 shares in the company, valued at $1,058,085. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of Integra Lifesciences stock in a transaction that occurred on Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the transaction, the insider now owns 134,134 shares of the company’s stock, valued at $8,475,927.46. The disclosure for this sale can be found here. Insiders have sold 56,592 shares of company stock valued at $3,573,584 over the last quarter. Company insiders own 5.10% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Recommended Story: How to Invest in a Bull Market
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.